TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03330327

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HM12470
Description: HM12470 is a long-acting insulin analogue

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HM12470
Description: HM12470 is a long-acting insulin analogue

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HM12470
Description: HM12470 is a long-acting insulin analogue
Study: NCT00703313

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.5% levofloxacin ophthalmic solution
Description: 1 drop instilled at each visit

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% moxifloxacin hydrochloride ophthalmic solution
Description: 1 drop instilled at each visit

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.3% gatifloxacin ophthalmic solution
Description: 1 drop instilled at each visit
Study: NCT02844127

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Implantable Cardioverter Defibrillator (ICD)
Description: Patients will receive an Implantable Cardioverter Defibrillator (ICD), with the leads implanted in either the apex or the septum as the first location. After defibrillation threshold is determined, the leads position will be changed to the second location and DFT will be determined again.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Implantable Cardioverter Defibrillator (ICD)
Description: Patients will receive an Implantable Cardioverter Defibrillator (ICD), with the leads implanted in either the apex or the septum as the first location. After defibrillation threshold is determined, the leads position will be changed to the second location and DFT will be determined again.
Study: NCT01323907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omegaven IV lipid emulsion
Description: For infants meeting inclusion criteria and whose guardians consent to participation, Omegaven will be initiated at the dose of 0.5gram/kg/day and is infused over 24 hours for 1-2 days and then advanced to 1 gram/kg/day. Omegaven will be infused intravenously through a central or peripheral catheter alone or in conjunction with parenteral nutrition.
Study: NCT03971188

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trapeziectomy with Internal Brace
Description: Trapeziectomy is performed in standard fashion. Longitudinal traction applied to thumb. Suture anchor with suture tape is inserted into drill hole at radial thumb metacarpal base. A second suture anchor is inserted into a drill hole at the radial base of the index metacarpal such that the suture tape suspends the thumb at the natural groove. Thumb position and tension assessed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trapeziectomy with Internal Brace
Description: Trapeziectomy is performed in standard fashion. Longitudinal traction applied to thumb. Suture anchor with suture tape is inserted into drill hole at radial thumb metacarpal base. A second suture anchor is inserted into a drill hole at the radial base of the index metacarpal such that the suture tape suspends the thumb at the natural groove. Thumb position and tension assessed.
Study: NCT04626414

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric maltol capsule
Description: single dose of 30 mg capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric maltol capsule
Description: single dose of 30 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric maltol suspension
Description: single dose of 30mg (5ml) oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric maltol suspension
Description: single dose of 30mg (5ml) oral suspension
Study: NCT00712374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulfadoxine-pyrimethamine plus amodiaquine
Description: SP+AQ on three occasions during the malaria transmission season~Intermittent Preventive Treatment with sulfadoxine-pyrimethamine plus amodiaquine
Study: NCT02818699

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 280mg placebo capsule containing only maltodextrin, twice daily, one with breakfast, one with dinner, for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EMIQ
Description: 280mg placebo capsule containing 180 mg EMIQ and 100mg maltodextrin, twice daily, one with breakfast, one with dinner, for 12 weeks
Study: NCT00586365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: 500 mg Naproxen twice a day for two weeks
Study: NCT00766792

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nocturnal dialysis
Description: Switch to nocturnal dialysis (3 times 480 min/week)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard dialysis
Description: Standard dialysis (3 times 240-270 min/week)
Study: NCT00575861

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zileuton
Description: zileuton (Zyflo) 600mg qid for 2hr and for 30 days
Study: NCT02303925

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NESTER COILS
Study: NCT04007159

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serum
Description: Participants will be topically applied serum to the dorsum, under a semi-occlusive patch (0.02 milliliters per centimeters square \[mL/cm\^2\] of serum in an individual cell of patch)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lotion
Description: Participants will be topically applied lotion to the dorsum, under a semi-occlusive patch (0.02mL/cm\^2 of lotion in an individual cell of patch)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cream
Description: Participants will be topically applied cream to the dorsum, under a semi-occlusive patch (0.02mL/cm\^2 of cream in an individual cell of patch)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Participants will be topically applied normal saline to the dorsum, under a semi-occlusive patch (0.02mL/cm\^2 of normal saline in an individual cell of patch)
Study: NCT02388295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3241
Description: Drug: AZD3241 administered for 12 weeks orally as a tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match AZD3241 administered for 12 weeks orally as a tablet.
Study: NCT01755988

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational website (in addition to usual care).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Website and interactive platform with telemonitoring.
Study: NCT02786069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propionyl L-carnitine Hydrochloride
Description: 500mg/ tablet; for oral administration, 1 dosage form is set for this trial: 1g, 2g and 4g.
Study: NCT01057277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001(Afinitor)
Description: Rad001 in combination withCisplatin and Concurrent RT
Study: NCT01036399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral Lenalidomide is initiated on day 1 of cycle 1at the dose of 25 mg daily for 21 days with 7 days rest (28 day cycle) for a total of 4 cycles.
Study: NCT04024592

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biodex System 4
Description: Reliability and validity of isokinetic strength measurement of the knee, hip and ankle in typically developing children.
Study: NCT02906800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: The digoxin dose will be adjusted to achieve a plasma concentration of 0.6-1.2 ng/ml according to current recommendations in heart failure patients (doses adapted to renal function, comorbidities, concomitant medications, age, and plasma concentration). The risk related to digoxin treatment will be minimized in our study since the duration of exposure to digoxin will be limited to 9 days every 3 weeks for 3 cycles (total duration of treatment 27 days).
Study: NCT03382093

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personalized Feedback Intervention
Description: Personalized Feedback Intervention for smoking and anxiety.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Information Control
Description: Smoking Information with no personalized feedback.
Study: NCT03276299

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: six minute walking test
Description: six minute walking test
Study: NCT03350347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molidustat (BAY85-3934)
Description: Starting dose of 25 mg or 50 mg molidustat once daily (OD) will be titrated based on the subject's Hb response

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: Starting dose and frequency of darbepoetin alfa are based on previous ESA. The dose will be titrated based on the subject's Hb response
Study: NCT03682159

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manual lymphatic drainage
Description: The intervention group received the same conventional postoperative cares as the control group, but also underwent 5 sessions of manual lymphatic drainage (MLD)
Study: NCT01304641

Intervention type: OTHER
Intervention: Atorvastatin Initiators
Description: Retrospective database analysis no intervention performed.

Intervention type: OTHER
Intervention: Simvastatin Initiators
Description: Retrospective database analysis no intervention performed.
Study: NCT03596944

Intervention type: DRUG
Intervention: Statin
Description: Prescribed with statins for primary prevention
Study: NCT02286388

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: A one-step partial caries removal procedure for the treatment of deep carious lesions in posterior permanent teeth.
Description: Instruments and procedures:~* Soprolife® (Acteon, La Ciotat, France) dental imaging device to detect dentinal infection status. The green-black light indicates infected dentin, red indicates infected/affected dentin and green indicates healthy dentinal tissue.~* Sterile round bur under water spray coolant followed by final excavation with hand instruments The clinician will remove the superficial necrotic and demineralized dentin with complete excavation of the peripheral demineralized dentin, avoiding excavation close to the pulp.~Hand instruments will be used for final excavation following clinical criteria guidelines (color of residual dentin and probe resistance) and taking in to consideration the color data obtained by the Soprolife® camera.~The operator will stop excavating when the dentin close to the pulp appears red (for infected dentin).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: A one-step partial caries removal procedure for the treatment of deep carious lesions in posterior permanent teeth.
Description: Instruments and procedures:~* Soprolife® (Acteon, La Ciotat, France) dental imaging device to detect dentinal infection status. The green-black light indicates infected dentin, red indicates infected/affected dentin and green indicates healthy dentinal tissue.~* Sterile round bur under water spray coolant followed by final excavation with hand instruments The clinician will remove the superficial necrotic and demineralized dentin with complete excavation of the peripheral demineralized dentin, avoiding excavation close to the pulp.~Hand instruments will be used for final excavation following clinical criteria guidelines (color of residual dentin and probe resistance) and taking in to consideration the color data obtained by the Soprolife® camera.~The operator will stop excavating when the dentin close to the pulp appears red (for infected dentin).
Study: NCT01644253

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20 mg/kg TRU-016 + Rituximab
Description: TRU-016: 10 mg/kg for first dose, all subsequent doses 20 mg/kg, IV once weekly for 8 weeks followed by 4 monthly doses~Rituximab: 375 mg/m2 for first dose, all subsequent doses 500 mg/m2, IV once weekly for 8 weeks followed by 4 monthly doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20 mg/kg TRU-016 + Rituximab
Description: TRU-016: 10 mg/kg for first dose, all subsequent doses 20 mg/kg, IV once weekly for 8 weeks followed by 4 monthly doses~Rituximab: 375 mg/m2 for first dose, all subsequent doses 500 mg/m2, IV once weekly for 8 weeks followed by 4 monthly doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10 mg/kg TRU-016 + Rituximab
Description: TRU-016: 6 mg/kg for first dose, all subsequent doses 10 mg/kg, IV on Day 1, 8 and 15, followed by 5 monthly doses~Rituximab: 375 mg/m2 for first dose, all subsequent doses 500 mg/m2, IV following TRU-016 schedule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRU-016 20 mg/kg + Obinutuzumab
Description: TRU-016: 6 mg/kg on Day 1, 20 mg/kg on Day 8 and 15, then 20 mg/kg once a month for 5 months~Obinutuzumab: 100 mg on Day 1, 900 mg on Day 2, 1,000 mg on Day 8 and 15, then 1,000 mg once a month for 5 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRU-016 6-20 mg/kg + idelalisib + rituximab
Description: TRU-016: 6 mg/kg on Days 15-36 weekly, 10 mg/kg on Days 43 and 50, then 20 mg/kg once a month for 5 months.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRU-016 10-20 mg/kg + ibrutinib
Description: TRU-016: Dosed weekly for 8 weeks followed by 4 monthly intravenous (IV) infusions. The first dose will be 10 mg/kg and all subsequent doses will be 20 mg/kg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRU-016 10-20 mg/kg + ibrutinib
Description: TRU-016: Dosed weekly for 8 weeks followed by 4 monthly intravenous (IV) infusions. The first dose will be 10 mg/kg and all subsequent doses will be 20 mg/kg.
Study: NCT02548065

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balneotherapy
Description: Bath with mineral water named Debole of Vetriolo at 36°C, 15 minutes for 12 consecutive days in bathtubs

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Bath with Thermal tap water
Study: NCT02415790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2027
Description: Part A: E2027 capsules will be administered orally in doses of 10 mg to 1200 mg in Part A and in Part B, C, and D at doses not exceeding the highest dose achieved in Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2027
Description: Part A: E2027 capsules will be administered orally in doses of 10 mg to 1200 mg in Part A and in Part B, C, and D at doses not exceeding the highest dose achieved in Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2027
Description: Part A: E2027 capsules will be administered orally in doses of 10 mg to 1200 mg in Part A and in Part B, C, and D at doses not exceeding the highest dose achieved in Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2027
Description: Part A: E2027 capsules will be administered orally in doses of 10 mg to 1200 mg in Part A and in Part B, C, and D at doses not exceeding the highest dose achieved in Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2027 matching placebo
Description: E2027 matching placebo capsule will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2027 matching placebo
Description: E2027 matching placebo capsule will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2027 matching placebo
Description: E2027 matching placebo capsule will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2027 matching placebo
Description: E2027 matching placebo capsule will be administered.
Study: NCT03939234

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PD-L1, PD-L2 peptides with Montanide ISA51
Description: PD-L1: 19 amino acid sequence from the PD-L1 protein; PD-L2: 21 amino acid sequence from the PD-L2 protein; The peptides are dissolved in dimethyl sulphoxide (DMSO) and mixed with Montanide.
Study: NCT01019564

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Complete Easy Rub Formula MPS
Description: Multi-purpose solution

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aquify MPS
Description: Multi-purpose solution
Study: NCT04401657

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fractional flow reserve with adenosine stress testing
Description: ECG, FFR, and two-dimensional echocardiographic monitoring will be continued before, during and after adenosine infusion.
Study: NCT01644253

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRU-016 10-20 mg/kg + bendamustine
Description: TRU-016 dosed 10 mg/kg for the first dose and then 20 mg/kg weekly for 2 cycles, followed by dosing every other week for an additional 4 cycles (cycle = 28 days). Bendamustine (90 mg/m2 on days 2 and 3 of cycle 1 and then days 1 and 2 of cycles 2 to 6) will be infused after completion of TRU-016. If a patient is benefiting with stable disease or better, then TRU-016 may continue to be dosed every 3 weeks after the first 6 cycles; bendamustine will not be dosed beyond 6 cycles.
Study: NCT02296411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5259 12.5 µg
Description: comparison of CHF5259 versus placebo over 2 treatment periods of 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CHF 5259 placebo
Description: comparison of CHF5259 versus placebo over 2 treatment periods of 6 weeks
Study: NCT02476487

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG PET CT
Description: FDG-PET CT will be performed on day 7-14 since the first positive blood culture. 1. Patients fulfilling current criteria for a short course (2 weeks) of antibiotic treatment: treatment will be prolonged if PET CT demonstrates a focus of residual infection.~2. Patients with risk factors mandating prolonged antibiotic treatment (4-6 weeks) according to current guidelines without IE: antibiotics will be stopped at 2 weeks if PET CT is normal.
Study: NCT02649634

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: The semi-structured MI protocol was a 45-60 minute intervention based on general MI principles and guidelines, MI strategies specific to health care practice, and MI principles for obesity treatment. The MI protocol included the following components: (1) eliciting concerns about weight; (2) exploring ambivalence; (3) assessing importance and confidence for change; (4) writing a decisional balance; (5) bolstering self-efficacy; (6) looking towards the future; and (8) eliciting ideas for possible changes participant could make to work towards weight loss. Although there was slight variation, the protocol for both MI sessions consisted of similar components.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: The attention control interview was a semi-structured interview ascertaining information relevant to health history, weight history, diet history, dietary and physical activity habits. The majority of questions for the control interviews were drawn from the Behavioural Weight Loss Program intake application. It was designed to be structurally equivalent to the MI session in terms of length of session, timing of sessions, and treatment modality. The goal of the attention-control interview was to provide a pseudo-intervention that controlled for factors common to attending treatment (e.g., attending treatment sessions, having personal contact with a therapist, discussing weight-related issues).
Study: NCT04471896

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Joovv Mini
Description: Infrared light therapy uses certain wavelengths of light that are delivered to the face. This study will use the Joovv Mini.
Study: NCT01136395

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375mg/m2 4 weeks before ABOi LD transplantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: living donor transplantation
Description: living donor transplantation (ABO compatible) to be compared with deceased donor transplantation (ABO compatible) in its impact on immunological parameters of graft outcome and on viral replication (CMV, EBV, BK/JC), respectively

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: living donor transplantation
Description: living donor transplantation (ABO compatible) to be compared with deceased donor transplantation (ABO compatible) in its impact on immunological parameters of graft outcome and on viral replication (CMV, EBV, BK/JC), respectively

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: deceased donor transplantation
Description: deceased donor transplantation (ABO compatible) to be compared with living donor transplantation (ABO compatible) in its impact on immunological parameters of graft outcome and on viral replication (CMV, EBV, BK virus (BKV), JC virus (JCV)), respectively
Study: NCT03931174

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Addiction Technology Transfer Center (ATTC) Training Strategy
Description: Participating organizations will receive training consisting of 3 components: 1) didactic workshop - full-day workshop led by a contingency management (CM) expert for both CM staff and leaders, 2) performance feedback - submission of CM session recordings for review and performance feedback at least monthly for 9 months for CM staff, and 3) staff coaching - monthly provider coaching calls led by a CM expert for 9 months for both CM staff and leaders.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Addiction Technology Transfer Center (E-ATTC) Training Strategy
Description: Participating organizations will receive all of the elements of the ATTC control condition. In addition, organizations will receive two additional elements: 1) Implementation Sustainment Facilitation - monthly coaching calls for CM leaders and staff focused on sustainment, 2) Pay for Performance - participating CM staff will have the opportunity to earn monthly monetary bonuses for achieving pre-defined implementation goals for 9 months.
Study: NCT00607048

Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel + Carboplatin + CP-870,893
Description: Paclitaxel is administered intravenously on day 1 of a 21-day cycle at a dose of 175 mg/m\^2. Carboplatin is administered intravenously on day 1 of a 21-day cycle at AUC 6. CP-870,893 is administered intravenously on DAY 3 of a 21-day cycle in escalating doses (0.1 mg/kg and 0.2 mg/kg)

Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel + Carboplatin + CP-870,893
Description: Paclitaxel is administered intravenously on day 1 of a 21-day cycle at a dose of 175 mg/m\^2. Carboplatin is administered intravenously on day 1 of a 21-day cycle at AUC 6. CP-870,893 is administered intravenously on DAY 8 of a 21-day cycle in escalating doses (0.1 mg/kg and 0.2 mg/kg)